Stifel Maintains Buy on Revance Therapeutics, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Annabel Samimy maintains a Buy rating on Revance Therapeutics (NASDAQ:RVNC) but lowers the price target from $24 to $20.
August 09, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Stifel analyst Annabel Samimy maintains a Buy rating on Revance Therapeutics but lowers the price target from $24 to $20.
The Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100